2型糖尿病患者脂肪分布与胰岛功能的相关性研究

注册号:

Registration number:

ChiCTR2200062884 

最近更新日期:

Date of Last Refreshed on:

2023-04-04 17:01:39 

注册时间:

Date of Registration:

2022-08-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

2型糖尿病患者脂肪分布与胰岛功能的相关性研究

Public title:

Correlation between fat distribution and β-cell function in patients with type 2 diabetes mellitus

注册题目简写:

English Acronym:

研究课题的正式科学名称:

2型糖尿病患者脂肪分布与胰岛功能的相关性研究

Scientific title:

Correlation between fat distribution and β-cell function in patients with type 2 diabetes mellitus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐玲玲 

研究负责人:

徐玲玲 

Applicant:

Lingling Xu 

Study leader:

Lingling Xu 

申请注册联系人电话:

Applicant telephone:

+86 13538838066

研究负责人电话:

Study leader's
telephone:

+86 13538838066

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lucylingl@126.com

研究负责人电子邮件:

Study leader's E-mail:

lucylingl@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市宝安区新湖路1333号

研究负责人通讯地址:

广东省深圳市宝安区新湖路1333号

Applicant address:

1333 Xinhu Road, Baoan District, Shenzhen, Guangdong, China

Study leader's address:

1333 Xinhu Road, Baoan District, Shenzhen, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学深圳医院

Applicant's institution:

Shenzhen Hospital, Southern Medical University

研究负责人所在单位:

南方医科大学深圳医院

Affiliation of the Leader:

Shenzhen Hospital, Southern Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NYSZYYEC20220017

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医科大学深圳医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shenzhen Hospital of Southern Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-06-08 00:00:00

伦理委员会联系人:

郑泽微

Contact Name of the ethic committee:

Zheng Zewei

伦理委员会联系地址:

广东省深圳市宝安区新湖路1333号

Contact Address of the ethic committee:

1333 Xinhu Road, Baoan District, Shenzhen, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学深圳医院

Primary sponsor:

Shenzhen Hospital, Southern Medical University

研究实施负责(组长)单位地址:

广东省深圳市宝安区新湖路1333号南方医科大学深圳医院

Primary sponsor's address:

1333 Xinhu Road, Baoan District, Shenzhen, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

南方医科大学深圳医院

具体地址:

宝安区新湖路1333号

Institution
hospital:

Shenzhen Hospital, Southern Medical University

Address:

133Xinhu Road, Baoan District

经费或物资来源:

深圳市科技计划项目;2021年中国内分泌代谢英才研究项目

Source(s) of funding:

Science and Technology Planning Project of Shenzhen Municipality; Young Scientific Talent Research Project of China Endocrinology and Metabolism

研究疾病:

2型糖尿病  

Target disease:

type 2 diabetes

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

探讨2型糖尿病患者脂肪分布与胰岛功能的相关性。  

Objectives of Study:

To investigate the relationship between fat distribution and beta-cell function in patients with type 2 diabetes mellitus.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.近期糖尿病急性并发症:糖尿病酮症酸中毒、乳酸酸中毒、高渗性昏迷等;
2.影响糖脂代谢的其他原因:甲状腺功能亢进症、甲状腺功能减退症、库欣综合征、下丘脑及垂体病变、使用糖皮质激素治疗等;
3.孕妇或哺乳期妇女;
4.急慢性传染病或癌症患者。

Exclusion criteria:

1. Recent diabetic acute complications, including diabetic ketoacidosis, lactic acidosis, hyperosmotic coma;
2. Glucolipid metabolism affected by other factors, such as hyperthyroidism, hypothyroidism, Cushing's syndrome, lesion of hypothalamus and pituitary, long-term glucocorticoids therapy;
3. Pregnant or lactating women;
4. Patients with acute or chronic infectious diseases or cancer.

研究实施时间:

Study execute time:

From 2022-08-01 00:00:00 To 2024-08-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-08-22 00:00:00 To 2023-08-01 00:00:00

干预措施:

Interventions:

组别:

内脏脂肪面积<100cm2

样本量:

82

Group:

visceral fat area < 100 cm2

Sample size:

干预措施:

干预措施代码:

Intervention:

non-intervention

Intervention code:

组别:

内脏脂肪面积≥100cm2

样本量:

82

Group:

visceral fat area >= 100 cm2

Sample size:

干预措施:

干预措施代码:

Intervention:

non-intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

深圳 

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

南方医科大学深圳医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen Hospital, Southern Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

内脏脂肪面积

指标类型:

主要指标

Outcome:

visceral fat area

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮下脂肪面积

指标类型:

主要指标

Outcome:

subcutaneous fat area

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖

指标类型:

主要指标

Outcome:

fasting blood glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

餐后血糖

指标类型:

主要指标

Outcome:

postprandial blood glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹C肽

指标类型:

主要指标

Outcome:

fasting C-peptide

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

餐后C肽

指标类型:

主要指标

Outcome:

postprandial C-peptide

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究为横断面研究,纳入研究的为2型糖尿病患者,根据患者的内脏脂肪面积水平分两组,不需要进行随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is a cross-sectional observational study in which patients with type 2 diabetes are divided into 2 groups according to their visceral fat area, without the need for random grouping.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024.12之前公开原始数据,网络上传至360云盘

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data will be open to public before 2023.12, and it will be uploaded to the cloud disk 360.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用SPSS24.0软件录入及分析数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Using SPSS24.0 software to input and analyse data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-08-22 17:03:15